Share This:

Scientific Symposia on Ocular Toxicity

Poster for May 2005 ocular symposia

Symposium I: Mechanisms of Chemically-Induced Ocular Injury and Recovery
(May 11-12, 2005)

Symposium II: Minimizing Pain and Distress in Ocular Toxicity Testing
(May 13, 2005)

National Institutes of Health - Bethesda, MD

Organized by ICCVAM, NICEATM and the European Centre for the Validation of Alternative Methods (ECVAM)
Sponsored by ICCVAM, NICEATM, ECVAM and the European Cosmetic, Toiletry and Perfumery Association

Presentation summarizing the symposia
Scientific Advisory Committee on Alternative Toxicological Methods meeting, December 12, 2005

Detailed Symposia Goals and Objectives

View Detailed Agenda for both Symposia
(Agenda includes references and information about previous relevant symposia)

Symposium I - Mechanisms of Chemically-Induced Ocular Injury and Recovery

Symposium Goals: to identify research needed to address current knowledge gaps and to advance the development and validation of ocular toxicity test methods for regulatory testing that provide for protection of human health while reducing, refining (less pain and distress), and/or replacing the use of animals.

The participants in Symposium I made the following recommendations:

  • Data collected from objective, quantitative endpoints and biomarkers should be used to assess the severity of chemically-induced ocular injuries in animal safety studies and human accidental exposures.
  • The routine collection of this data can be expected to:
    • Provide insights into chemical-specific mechanisms of ocular injury and recovery
    • Support the development and validation of more predictive mechanism-based in vitro test models
    • Improve the accuracy and reliability of ocular hazard assessments
    • Aid in identifying predictive, mechanism-based earlier humane endpoints

Abbreviated Agenda

  • Session 1 – Overview of Recent Initiatives and Regulatory Requirements for Ocular Toxicity Testing
  • Session 2 – Current Ocular Injury and Toxicity Assessments
  • Session 3 – Mechanisms and Biomarkers of Ocular Injury and Recovery
  • Session 4 – Current In Vitro Models of Ocular Injury and Recovery
  • Session 5 – In Vivo Quantitative Objective Endpoints to Support Development and Validation of Predictive In Vitro Models
  • Summary of Symposium Discussions
Symposium II - Minimizing Pain and Distress in Ocular Toxicity Testing

Symposium Goals: To review current understanding of the sources and mechanisms of pain and distress in ocular toxicity testing; identify current best practices for preventing, recognizing and alleviating ocular pain and distress; and to identify additional research, development, and validation studies necessary to support scientifically valid ocular testing procedures that avoid pain and distress.

The participants in Symposium II made the following recommendations:

  • Pre-treatment with topical or general anaesthesia should be used routinely to avoid pain from topical application of test substances
  • Systemic analgesics should be administered prior to test article application and continued until injuries resolve or the study is terminated
  • Ocular injuries predictive of severe or irreversible ocular damage should be used as earlier humane endpoints
  • Objective, quantitative measurements should be collected during ocular studies to assist in identifying earlier, more humane endpoints. Data from these measurements are also critical to the development and validation of more predictive in vitro methods.

Abbreviated Agenda

  • Session 1 – Recognition and Sources of Pain in Ocular Injuries and Ocular Safety Testing
  • Session 2 – Alleviation and Avoidance of Ocular Injury and Pain
  • Session 3 – Biomarkers Predictive of Severe and/or Irreversible Effects that Might Serve as Earlier Humane Endpoints for Ocular Studies
  • Summary of Symposium Discussions